Insider trade

Director sold ~$340K of REGN shares in the open market

Traded Sep 2, 2026 · Filed Sep 3, 2026

~$340K
Reported value · 400 sh @ $850.00: 603
Holds after · shares reported: −14.7%
stock since the trade · S&P 500 +1.3%, $852.03 → $726.47 on Oct 5

Why it stands out

A board member of Regeneron Pharmaceuticals sold $340K of Regeneron Pharmaceuticals shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 2, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 3, 2026

Director$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$340,000

Shares × reported transaction price

Timing vs results

34 days after results of Jul 30, 2026, 34 days before results of Oct 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $852.03 on Sep 2, 2026, at its 52-week high, after a 31% rise over the previous 30 trading days

52-week range $555.51 (Sep 25, 2025) to $852.03 (Sep 2, 2026), 100% of the way up, from 252 adjusted closes. 30 trading days earlier: $651.18 on Jul 22, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Jul 16, 2026 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

2 such cases were open. Cheatham v. Regeneron Pharmaceuticals, Inc., docket 7:26-cv-06026, via CourtListener (court records). Nature of suit 850, company named as first defendant

FDA decision near the trade

FDA approved Pasatru on Aug 19, 2026, 14 days before this trade.

Biologic approved. Active ingredient: Garetosmab-Grts. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	−5.6%	−0.8%	−4.8%
30 days	−12.2%	+0.6%	−12.8%

Past results only. Not a forecast.

Source receipt

Record ID: 0001992352-26-000007
Filed / recorded: Sep 3, 2026, 8:47 PM UTC
Added to OQRO: Oct 2, 2026, 12:28 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: REGENERON PHARMACEUTICALS, INC.
Issuer CIK: 872589
Ticker: REGN
Reporting person: Kathryn Guarini
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Sep 2, 2026
Transaction code: S
Shares / units: 400
Price per share: $850.00
Acquired / disposed: Disposed (D)
Shares owned after: 603
Ownership form: Direct
Amendment: No

Footnotes from the filing

Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026.

Around the same time

Officer plans to sell ~$969K of Regeneron Pharmaceuticals

Planned, from pay5w ago

Officer sold ~$1.03M of Regeneron Pharmaceuticals

Scheduled in advance5w ago

Officer sold ~$970K of Regeneron Pharmaceuticals

Scheduled in advance5w ago